{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:58Z","timestamp":1767134938586,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":60,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd008858.pub2","type":"reference-entry","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T13:19:26Z","timestamp":1349961566000},"source":"Crossref","is-referenced-by-count":17,"title":["Vaccines for preventing herpes zoster in older adults"],"prefix":"10.1002","author":[{"given":"Anna MZ","family":"Gagliardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda Nazar\u00e9","family":"Gomes Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R","family":"Torloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo GO","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,17]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD008858.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/514265","article-title":"A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older","volume":"178","author":"Berger","year":"1998","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0264-410X(99)00510-1","article-title":"Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial","volume":"18","author":"Trannoy","year":"2000","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clinical and Vaccine Immunology"},{"issue":"25","key":"10.1002\/14651858.CD008858.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/S0264-410X(99)00552-6","article-title":"Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older","volume":"18","author":"Levine","year":"2000","journal-title":"Vaccine"},{"issue":"25","key":"10.1002\/14651858.CD008858.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1016\/j.vaccine.2010.04.003","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster","volume":"28","author":"Mills","year":"2010","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4161\/hv.7.11.17982","article-title":"Safety and tolerability of zoster vaccine in adults \u2265 60 years old","volume":"7","author":"Murray","year":"2011","journal-title":"Human Vaccines"},{"key":"10.1002\/14651858.CD008858.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"Journal of Infectious Diseases"},{"issue":"22","key":"10.1002\/14651858.CD008858.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1532-5415.2010.03021.x","article-title":"Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults","volume":"58","author":"Schmader","year":"2010","journal-title":"Journal American Geriatrics Society"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study a randomized trial","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.vaccine.2006.10.027","article-title":"Safety and tolerability of a high-potency zoster vaccine in adults \u2265 50 years of age","volume":"25","author":"Tyring","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \u226560 years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/vim.1994.7.31","article-title":"Immune response to secondary immunization with live or Inactivated VZV vaccine in elderly adults","volume":"7","author":"Hayward","year":"1994","journal-title":"Viral Immunology"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/vim.1996.9.241","article-title":"Varicella zoster virus specific cytotoxicity following secondary immunization with live or killed vaccine","volume":"9","author":"Hayward","year":"1996","journal-title":"Viral Immunology"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1532-5415.2007.01109.x","article-title":"Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi","volume":"55","author":"Irwin","year":"2007","journal-title":"Journal American Geriatrics Society"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older","volume":"55","author":"Kerzner","year":"2007","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD008858.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.vaccine.2006.11.011","article-title":"Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults","volume":"25","author":"Macaladad","year":"2007","journal-title":"Vaccine"},{"issue":"41","key":"10.1002\/14651858.CD008858.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1016\/j.vaccine.2007.07.051","article-title":"Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine","volume":"25","author":"Patterson-Bartlett","year":"2007","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008858.pub2-BIB20|cit20","unstructured":"NCT00434577 Safety and immunogenicity of the zoster vaccine GSK1437173A in elderly subjects http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00434577?term=Zoster+vaccine+AND+adults&rank=32"},{"key":"10.1002\/14651858.CD008858.pub2-BIB21|cit21","unstructured":"A double-blind, randomised, placebo-controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunization with V212\/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers Ongoing study"},{"key":"10.1002\/14651858.CD008858.pub2-BIB22|cit22","unstructured":"Efficacy, safety and immunogenicity of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults aged >= 70 years Ongoing study"},{"issue":"22","key":"10.1002\/14651858.CD008858.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Ageing, immunity, and the varicella-zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clinical Microbiology Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub2-BIB25|cit25","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007795.pub2","article-title":"Vaccination for preventing postherpetic neuralgia","author":"Chen","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jdermsci.2006.11.004","article-title":"Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea","volume":"45","author":"Cho","year":"2007","journal-title":"Journal of Dermatological Science"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcv.2010.01.003","article-title":"Disease burden of herpes zoster in Korea","volume":"47","author":"Choi","year":"2010","journal-title":"Journal of Clinical Virology"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory","volume":"5","author":"Coplan","year":"2004","journal-title":"Journal of Pain"},{"issue":"1-2","key":"10.1002\/14651858.CD008858.pub2-BIB29|cit29","first-page":"9-19","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pain.2008.12.022","article-title":"A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster","volume":"142","author":"Dworkin","year":"2009","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/jmv.21748","article-title":"No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia","volume":"82","author":"Gatti","year":"2010","journal-title":"Journal of Medical Virology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008858.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ophtha.2007.10.015","article-title":"Preventing herpes zoster through vaccination","volume":"115","author":"Gelb","year":"2008","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"635-45","DOI":"10.1056\/NEJM200003023420906","article-title":"Neurologic complications of the reactivation of varicella zoster virus","volume":"342","author":"Gilden","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice: herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008858.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF00439226","article-title":"Health state valuations from the general public using the visual analogue scale","volume":"5","author":"Gudex","year":"1996","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD008858.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/00365540110077218","article-title":"Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster","volume":"34","author":"Haanpaa","year":"2002","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s15010-007-6347-x","article-title":"Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel","volume":"36","author":"Heymann","year":"2008","journal-title":"Infection"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archderm.144.5.603","article-title":"Family history as a risk factor for herpes zoster: a case-control study","volume":"144","author":"Hicks","year":"2008","journal-title":"Archives of Dermatology"},{"issue":"7414","key":"10.1002\/14651858.CD008858.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD008858.pub2-BIB40|cit40","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","article-title":"Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales","volume":"27","author":"Hoek\u00a0AJ","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/003591576505800106","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proceedings of the Royal Society of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and post herpetic neuralgia in older adults","volume":"145","author":"Hornberger","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2340\/00015555-0729","article-title":"Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006","volume":"89","author":"Jih","year":"2009","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD008858.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"342-8","DOI":"10.1086\/421942","article-title":"Acute pain in herpes zoster and its impact on health-related quality of life","volume":"39","author":"Katz","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0300-8932(97)73190-7","article-title":"Investigation methods in clinical cardiology (IV) clinical measurements in cardiology: validity and errors of measurement","volume":"50","author":"Latour","year":"1997","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda"},{"key":"10.1002\/14651858.CD008858.pub2-BIB47|cit47","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD008858.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1212\/WNL.45.12_Suppl_8.S52","article-title":"Herpes zoster and quality of life: a self-limited disease with severe impact","volume":"45","author":"Lydick","year":"1995","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008858.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/erv.10.31","article-title":"Herpes zoster: a common disease that can have a devastating impact on patients' quality of life","volume":"9","author":"McElhaney","year":"2010","journal-title":"Expert Review of Vaccines"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1517\/14656560902808502","article-title":"The treatment of varicella-zoster virus infection and its complications","volume":"10","author":"Partridge","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD008858.pub2-BIB51|cit51","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/651078","article-title":"Increasing incidence of herpes zoster among veterans","volume":"50","author":"Rimland","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4065\/84.3.274","article-title":"Herpes zoster (shingles) and postherpetic neuralgia","volume":"84","author":"Sampathkumar","year":"2009","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/10489140-000000000-00000","article-title":"Zoster vaccine (Zostavax\u00ae) a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults","volume":"27","author":"Sanford","year":"2010","journal-title":"Drugs and Aging"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","article-title":"Herpes zoster pain and discomfort on functional status and quality of life in older adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clinical Journal of Pain"},{"issue":"Suppl","key":"10.1002\/14651858.CD008858.pub2-BIB56|cit56","first-page":"207-15","article-title":"The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine","volume":"197","author":"Schmader","year":"2008","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3949\/ccjm.75a.08046","article-title":"Who should receive the shingles vaccine?","volume":"76","author":"Singh","year":"2009","journal-title":"Cleveland Clinic Journal of Medicine"},{"key":"10.1002\/14651858.CD008858.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1128\/CVI.00407-08","article-title":"Comparation of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older","volume":"16","author":"Sutradhar","year":"2009","journal-title":"Clinical and Vaccine Immunology"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008858.pub2-BIB60|cit60","first-page":"2","article-title":"The burden of herpes zoster and postherpetic neuralgia in the United States","volume":"107","author":"Weaver","year":"2007","journal-title":"Journal of the American Osteopathic Association"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008858.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008858.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:24:25Z","timestamp":1628533465000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008858.pub2"}},"subtitle":[],"editor":[{"given":"Anna MZ","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,10,17]]},"references-count":60,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008858.pub2","relation":{},"subject":[],"published":{"date-parts":[[2012,10,17]]}}}